PHAXIAM Therapeutics S.A. (0QSS.L)
EUR 1.76
(1.03%)
EUR 1.76
(1.03%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.32 Million EUR | -80.05% |
| 2022 | 6.64 Million EUR | 59.02% |
| 2021 | 4.17 Million EUR | 12.43% |
| 2020 | 3.71 Million EUR | -29.62% |
| 2019 | 5.28 Million EUR | 18.8% |
| 2018 | 4.44 Million EUR | 32.19% |
| 2017 | 3.36 Million EUR | -18.7% |
| 2016 | 4.13 Million EUR | 41.28% |
| 2015 | 2.92 Million EUR | 63.18% |
| 2014 | 1.79 Million EUR | 8.08% |
| 2013 | 1.66 Million EUR | -71.05% |
| 2012 | 5.73 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 546.5 Thousand EUR | -35.78% |
| 2024 Q2 | 546.5 Thousand EUR | 0.0% |
| 2023 Q2 | 139 Thousand EUR | 0.0% |
| 2023 FY | 1.32 Million EUR | -80.05% |
| 2023 Q3 | 197 Thousand EUR | 41.73% |
| 2023 Q4 | 851 Thousand EUR | 331.98% |
| 2023 Q1 | 139 Thousand EUR | -97.34% |
| 2022 Q3 | 470 Thousand EUR | 13.53% |
| 2022 FY | 6.64 Million EUR | 59.02% |
| 2022 Q4 | 5.22 Million EUR | 1011.49% |
| 2022 Q2 | 414 Thousand EUR | -23.19% |
| 2022 Q1 | 539 Thousand EUR | -30.72% |
| 2021 Q3 | 1.13 Million EUR | 36.39% |
| 2021 FY | 4.17 Million EUR | 12.43% |
| 2021 Q4 | 778 Thousand EUR | -31.27% |
| 2021 Q1 | 1.44 Million EUR | 73.91% |
| 2021 Q2 | 830 Thousand EUR | -42.36% |
| 2020 Q4 | 828 Thousand EUR | -20.46% |
| 2020 FY | 3.71 Million EUR | -29.62% |
| 2020 Q1 | 747 Thousand EUR | -46.72% |
| 2020 Q2 | 1.1 Million EUR | 47.52% |
| 2020 Q3 | 1.04 Million EUR | -5.54% |
| 2019 Q1 | 757 Thousand EUR | -57.5% |
| 2019 Q2 | 2.2 Million EUR | 191.68% |
| 2019 FY | 5.28 Million EUR | 18.8% |
| 2019 Q4 | 1.4 Million EUR | 53.06% |
| 2019 Q3 | 916 Thousand EUR | -58.51% |
| 2018 Q4 | 1.78 Million EUR | 344.14% |
| 2018 Q3 | 401 Thousand EUR | -62.21% |
| 2018 Q2 | 1.06 Million EUR | -11.88% |
| 2018 Q1 | 1.2 Million EUR | 140.8% |
| 2018 FY | 4.44 Million EUR | 32.19% |
| 2017 Q4 | 500 Thousand EUR | -53.53% |
| 2017 Q1 | 1.22 Million EUR | 40.86% |
| 2017 Q2 | 566 Thousand EUR | -53.68% |
| 2017 FY | 3.36 Million EUR | -18.7% |
| 2017 Q3 | 1.07 Million EUR | 90.11% |
| 2016 Q2 | 1.71 Million EUR | 151.32% |
| 2016 Q4 | 867.5 Thousand EUR | 0.0% |
| 2016 Q3 | 867.5 Thousand EUR | -49.53% |
| 2016 FY | 4.13 Million EUR | 41.28% |
| 2016 Q1 | 684 Thousand EUR | -12.7% |
| 2015 Q4 | 783.5 Thousand EUR | 0.0% |
| 2015 Q3 | 783.5 Thousand EUR | 15.05% |
| 2015 FY | 2.92 Million EUR | 63.18% |
| 2015 Q2 | 681 Thousand EUR | 0.0% |
| 2015 Q1 | 681 Thousand EUR | 25.21% |
| 2014 Q4 | 543.86 Thousand EUR | 0.0% |
| 2014 Q1 | 353.63 Thousand EUR | -11.86% |
| 2014 Q3 | 543.86 Thousand EUR | 53.79% |
| 2014 Q2 | 353.63 Thousand EUR | 0.0% |
| 2014 FY | 1.79 Million EUR | 8.08% |
| 2013 FY | 1.66 Million EUR | -71.05% |
| 2013 Q2 | 429.18 Thousand EUR | -0.0% |
| 2013 Q3 | 401.21 Thousand EUR | -6.52% |
| 2013 Q1 | 429.19 Thousand EUR | -84.09% |
| 2013 Q4 | 401.21 Thousand EUR | 0.0% |
| 2012 Q4 | 2.69 Million EUR | 0.0% |
| 2012 FY | 5.73 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Boiron SA | 493.24 Million EUR | 99.731% |
| Laboratorios Farmaceuticos Rovi, S.A. | 829.5 Million EUR | 99.84% |
| Vetoquinol SA | 529.27 Million EUR | 99.749% |
| Valneva SE | 153.71 Million EUR | 99.137% |
| AB Science S.A. | 970 Thousand EUR | -36.701% |
| Nanobiotix S.A. | 30.05 Million EUR | 95.589% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 136.63% |
| BioSenic S.A. | 543 Thousand EUR | -144.199% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 71.305% |
| Formycon AG | 77.69 Million EUR | 98.293% |